Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | CASP7 | P55210 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 14/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.50 |
| ▸ | FBP1 | P09467 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1256076 | 0.85 | ADORA2A (0.69) | L3MBTL1MEN1ALDH1A1POLBMAPT | |
| SCHEMBL1256201 | 0.83 | ADORA2A (0.56) | L3MBTL1MEN1ALDH1A1POLBMAPT | |
| SCHEMBL1255867 | 0.82 | ADORA2A (0.52) | L3MBTL1MEN1ALDH1A1POLBMAPT | |
| SCHEMBL1256514 | 0.82 | MEN1 (0.51) | L3MBTL1MEN1ALDH1A1POLBMAPT | |
| SCHEMBL1255464 | 0.81 | MEN1 (0.50) | L3MBTL1MEN1ALDH1A1POLBMAPT | |
| SCHEMBL1256138 | 0.81 | ADORA2A (0.51) | L3MBTL1MEN1ALDH1A1POLBMAPT | |
| SCHEMBL1256118 | 0.81 | ADORA2A (0.54) | L3MBTL1MEN1ALDH1A1POLBMAPT | |
| SCHEMBL1677366 | 0.81 | RORB (0.61) | L3MBTL1MEN1ALDH1A1POLBMAPT | |
| SCHEMBL1255518 | 0.80 | L3MBTL1 (0.60) | L3MBTL1MEN1ALDH1A1POLBMAPT | |
| SCHEMBL1256786 | 0.80 | ADORA2A (0.53) | L3MBTL1MEN1ALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1921077-B1 | AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-07-26 | — | — | EP | disclosed |
| EP-3002283-A1 | THIAZOLE DERIVATIVES | Kyowa Hakko Kirin Co., Ltd. (JP) | 2016-04-06 | — | — | EP | disclosed |
| US-8889718-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-11-18 | — | — | US | disclosed |
| US-20130267509-A1 | THIAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-10-10 | — | — | US | disclosed |
| US-7928098-B2 | Therapeutic and/or preventive agents for a sleep disorder | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-04-19 | — | — | US | disclosed |
| US-20100152162-A1 | THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-7718808-B2 | Thiazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| EP-1921077-A1 | AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1700856-A1 | THIAZOLE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267509-A1 | THIAZOLE DERIVATIVES | THRA, CHD8, CYP2C8 | L3MBTL1 436/4885MEN1 1954/4885ALDH1A1 1344/4885 |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | ADORA2A, ADORA3, ADORA1 | L3MBTL1 2473/4885MEN1 3769/4885ALDH1A1 2843/4885 |
| US-20100152162-A1 | THERAPEUTIC AND/OR PREVENTIVE AGENTS FOR A SLEEP DISORDER | HCRTR1, MTNR1A, HCRTR2 | L3MBTL1 1732/4885MEN1 4098/4885ALDH1A1 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.